<?xml version="1.0" encoding="utf-8"?>
<!-- generator="FeedCreator 1.8.0-dev (info@mypapit.net)" -->
<rss version="2.0"  xmlns:atom="http://www.w3.org/2005/Atom">
    <channel>
        <title>Pharma - News &amp; Analysis</title>
        <description></description>
        <link>http://pharma.industry-focus.net/</link>
        <lastBuildDate>Thu, 11 Jun 2026 17:24:48 GMT</lastBuildDate>
        <generator>FeedCreator 1.8.0-dev (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="e58c8b838aa5889c9584958c91cb8b8091">[email&#160;protected]</a>)</generator>
		<atom:link href="https://pharma.industry-focus.net/index.php?option=com_ninjarsssyndicator&amp;feed_id=1&amp;format=raw" rel="self" type="application/rss+xml" />        <item>
            <title>Govt. to open pharma retail outlets</title>
            <link>http://pharma.industry-focus.net/industry-policies/50-govt-to-open-pharma-retail-outlets.html</link>
            <description><![CDATA[Govt. assisted retails stores are to be opened across the country. These stores will be branded as ‘Jan Aushadhi’ and it will be operated 24x7 and these will be self-sustained units but will operate closely with Govt. health units initially. Bureau of Public Enterprises will streamline the process in consultation with state governments and NGO’s.
Current plan is to launch 20-40 JA stores across states. A clear picture will emerge later next month. The USP of these stores will be that they will sell unbranded medicines which will be substantially cheaper. (eg. New generation anti-biotic costs Rs.150 in private will cost Rs.30 here)
Some factors that could undermine this process could be bureaucratic delays and lack of clear substitution for branded medicines.  
 ]]></description>
			<pubDate>Fri, 30 Aug 2013 12:35:56 GMT</pubDate>
            <guid isPermaLink="false">http://pharma.industry-focus.net/industry-policies/50-govt-to-open-pharma-retail-outlets.html</guid>
        </item>
        <item>
            <title>Celestial Biologicals to set up GMP complaint facility in Ahmedabad</title>
            <link>http://pharma.industry-focus.net/latest-news/73-celestial-biologicals-to-set-up-gmp-complaint-facility-in-ahmedabad.html</link>
            <description><![CDATA[Celestial Biologicals Ltd (CBL) an associate of Intas and GE Healthcare has announced an collobaration to set up a GMP compliant plasma fractionation facility in Ahmedabad. The new facility will entail an investment of Rs. 1200 million and will become operational by early 2010. The planned initial capacity  will be 15000 liters and it will be subsequently scaled to 300000 liters.]]></description>
			<pubDate>Fri, 30 Aug 2013 12:35:56 GMT</pubDate>
            <guid isPermaLink="false">http://pharma.industry-focus.net/latest-news/73-celestial-biologicals-to-set-up-gmp-complaint-facility-in-ahmedabad.html</guid>
        </item>
        <item>
            <title>Cram business likely to get a boost in this slow-down period</title>
            <link>http://pharma.industry-focus.net/contract-research-and-manufacturing/58-cram-business-likely-to-get-a-boost-in-this-slow-down-period.html</link>
            <description><![CDATA[ With spiralling research costs, expiry of patent period, couple by advancement of Indian pharma companies will result in growth of contract research business. Many analyst predicts a growth of $ 3 biliion of cram business by 2015. Further, many Indian companies Divis Laboratories, Piramal Healthcare, Biocon have expanded recently their operations to accommodate this growth. Indian pharma industry, has similar strengths of IT (high skilled man-power at low costs, availability) is set to make this grow.  ]]></description>
			<pubDate>Fri, 30 Aug 2013 12:35:56 GMT</pubDate>
            <guid isPermaLink="false">http://pharma.industry-focus.net/contract-research-and-manufacturing/58-cram-business-likely-to-get-a-boost-in-this-slow-down-period.html</guid>
        </item>
        <item>
            <title>GE Healthcare ties-up with Spinco for its distribution</title>
            <link>http://pharma.industry-focus.net/component/content/article/46-pharma-news/pharma-distribution-a-licensing/66-ge-healthcare-ties-up-with-spinco-for-its-distribution.html</link>
            <description><![CDATA[ Spinco Biotech, the leading distributor in instrumentation and has presence in lifecare research, academic sector has entered into an agreement to GE Healthcare for distribution of its products. This will facilitate in early diagnosis of many ailments as Spinco has extensive network and it will help to offer total solutions.  ]]></description>
			<pubDate>Fri, 30 Aug 2013 12:35:56 GMT</pubDate>
            <guid isPermaLink="false">http://pharma.industry-focus.net/component/content/article/46-pharma-news/pharma-distribution-a-licensing/66-ge-healthcare-ties-up-with-spinco-for-its-distribution.html</guid>
        </item>
        <item>
            <title>Glaxo partners with Bangalore based Kermwell for R&amp;amp;D</title>
            <link>http://pharma.industry-focus.net/contract-research-and-manufacturing/62-glaxo-partners-with-bangalore-based-kermwell-for-rad.html</link>
            <description><![CDATA[GSK Consumer Healthcare, has partnered with Kermwell, Bangalore based contract manufacturer of pharma products for R&D work. Currently, Kermwell, does bottling, packaging for Glaxo for over a decade. The new R&D unit for Glaxo will come up at its existing unit in Bangalore and Kermwell has hired over 20 people to execute this contract. The R&D services include, clinical trials, stability studies, analytical services, formulation etc.,{backbutton}]]></description>
			<pubDate>Fri, 30 Aug 2013 12:35:56 GMT</pubDate>
            <guid isPermaLink="false">http://pharma.industry-focus.net/contract-research-and-manufacturing/62-glaxo-partners-with-bangalore-based-kermwell-for-rad.html</guid>
        </item>
        <item>
            <title>Pharma companies look at emerging markets to drive revenue</title>
            <link>http://pharma.industry-focus.net/insights/52-pharma-companies-look-at-emerging-markets-to-drive-revenue.html</link>
            <description><![CDATA[Pharma companies affected by downturn and exposures to foreign currencies is experiencing a slide in sales from developed markets while seeing a significant growth in sales from emerging markets like Egypt, Russia, Brazil and African markets. For companies like Glenmark, Ranbaxy sales have been up to emerging markets from 20% to as much as 60%. Many pharma will follow suit and will deploy aggressive strategies to introduce several medicines into these markets. Russia, CIS like Ukraine, Kazakhstan, Uzbekistan and Eastern Europe will have high entry barriers with few competitors are ideal for Indian pharma companies to exploit  {backbutton}   ]]></description>
			<pubDate>Fri, 30 Aug 2013 12:35:56 GMT</pubDate>
            <guid isPermaLink="false">http://pharma.industry-focus.net/insights/52-pharma-companies-look-at-emerging-markets-to-drive-revenue.html</guid>
        </item>
        <item>
            <title>Pfizer licences Aurobindo Pharma for 50 generics</title>
            <link>http://pharma.industry-focus.net/component/content/article/46-pharma-news/pharma-distribution-a-licensing/69-pfizer-licences-aurobindo-pharma-for-50-generics.html</link>
            <description><![CDATA[ Pfizer Inc, world largest manufacturer of drugs has signed an agreement to license 50 generic medicines including pills, injectables to Indian pharma maker Aurobindo Pharma.,  This move is seen as shifting the company’s focus on off-patent drugs.  This sourcing agreement will result in steady flow of revenue  for Aurobindo Pharma. As per the deal, Pfizer can have employees at Aurobindo production plants to ensure quality concerns which has become a key one after complaints against Indian pharma producer Ranbaxy.]]></description>
			<pubDate>Fri, 30 Aug 2013 12:35:56 GMT</pubDate>
            <guid isPermaLink="false">http://pharma.industry-focus.net/component/content/article/46-pharma-news/pharma-distribution-a-licensing/69-pfizer-licences-aurobindo-pharma-for-50-generics.html</guid>
        </item>
        <item>
            <title>Bharat Biotech launches new COMVAC5, a single shot pentavalent vaccine</title>
            <link>http://pharma.industry-focus.net/technology-trends/53-bharat-biotech-launches-new-comvac5-a-single-shot-pentavalent-vaccine.html</link>
            <description><![CDATA[ Bharat Biotech International Ltd, a Hyderabad based company that manufactures vaccines launched COMVAC5, a single shot vaccine which offers protection against haemophilus influenza, meningitis etc and contains tetanus, Hepatitis B, Hib, Pertusis, Diptheria. It is the first of kind of Hib vaccine manufactured indigenously without using cesium chloride.   ]]></description>
			<pubDate>Fri, 30 Aug 2013 12:35:56 GMT</pubDate>
            <guid isPermaLink="false">http://pharma.industry-focus.net/technology-trends/53-bharat-biotech-launches-new-comvac5-a-single-shot-pentavalent-vaccine.html</guid>
        </item>
        <item>
            <title>Zydus Cadila gets AAALAC certification</title>
            <link>http://pharma.industry-focus.net/technology-trends/56-zydus-cadila-gets-aaalac-certification.html</link>
            <description><![CDATA[Zydus Cadila ( Cadila Healthcare Ltd) has received full accreditation from AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International. AAALAC is an international body of experts which monitors animals used in lab tests and research programmes. Cadila has received this accreditation after a complete on-site evaluation of care of animals, facilities by experts.   ]]></description>
			<pubDate>Fri, 30 Aug 2013 12:35:56 GMT</pubDate>
            <guid isPermaLink="false">http://pharma.industry-focus.net/technology-trends/56-zydus-cadila-gets-aaalac-certification.html</guid>
        </item>
        <item>
            <title>New regulatory regime for pharma industry</title>
            <link>http://pharma.industry-focus.net/industry-overview/48-new-regulatory-regime-for-pharma-industry.html</link>
            <description><![CDATA[A friendly regulatory regime for pharma industry will come into force. Dept. of Pharmaceuticals has met major pharma companies to identify bottlenecks that mars pharma research. It plans to iron out difficulties  to provide a boost for pharma research in the country. It will facilitate faster approvals for various stages of animal and human experiments. Overall, it will be friendly to pharma companies, provide protection of research data at the same time prevent pharma companies to hold on patents only upto 20 years without extending the same by exclusive rights   ]]></description>
			<pubDate>Fri, 30 Aug 2013 12:35:56 GMT</pubDate>
            <guid isPermaLink="false">http://pharma.industry-focus.net/industry-overview/48-new-regulatory-regime-for-pharma-industry.html</guid>
        </item>
    </channel>
</rss>
<script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script>